SEARCH:   Advanced

Blood, 1 October 2009, Vol. 114, No. 14, pp. 2993-3000. Prepublished online as a Blood First Edition Paper on July 30, 2009; DOI 10.1182/blood-2009-05-223115. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2009-05-223115v1 114/14/2993    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Google Scholar Articles by Tang, R. Articles by Legrand, O. PubMed PubMed Citation Articles by Tang, R. Articles by Legrand, O. Related Collections Myeloid Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  MYELOID NEOPLASIA High Id1 expression is associated with poor prognosis in 237 patients with acute myeloid leukemia Ruoping Tang1,2, Pierre Hirsch13, Fanny Fava1,2, Simona Lapusan1, Christophe Marzac3, Irène Teyssandier3, Julia Pardo2, Jean-Pierre Marie1,2, and Ollivier Legrand1,2 1 Département d'Hématologie, Hôtel-Dieu, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris; 2 Université Pierre et Marie Curie, Inserm, Paris; and 3 Laboratoire d'Immunologie et Hématologie biologique, Hôpital Saint-Antoine, AP-HP, Paris, France Inhibitors of differentiation (Id) are a group of dominant inhibitors of basic helix-loop-helix transcriptional factors, which promote excessive proliferation, and also protect cells against drug-induced apoptosis in mammalians. Recently, Id1 has been identified as a common downstream target of several constitutively activated oncogenic tyrosine kinase, such as FLT3 internal tandem duplication, in leukemia cells. We analyzed Id1 expression as possible prognostic factor in 237 acute myeloid leukemia (AML) patients. High Id1 expression was associated with older age (P = .009) and with FLT3 internal tandem duplication (P = .003). However, 61% of the patients in the group of FLT3– AML were Id1+, suggesting that other tyrosine kinases are involved. In whole population, high Id1 expression independently predicted shorter disease-free survival (P = .05) and overall survival (P = .003). In young patients (age 60 years) with normal cytogenetics, Id1+ was, in multivariate analysis, associated with lower complete remission rates (P = .02), shorter disease-free survival (P = .02), and overall survival (P = .006). In conclusion, our data provide a new molecular marker for refining the risk classification of AML, especially in young patients with normal cytogenetic. Id1– patients with normal cytogenetic should be classified as favorable-risk leukemia. Id1, as a downstream target of constitutively activated tyrosine kinase, could be a suitable candidate for targeted therapy. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020